Skip to content
May 2015

Bernitsas Law advises Glaxo Smith Kline on Greek part of global joint venture with Novartis

Bernitsas Law represented Glaxo Smith Kline in the implementation of the local part of their global joint venture with Novartis, with a matter value of $16bn for the Oncology business and $7.1bn for the Vaccine business, a transaction which had a significant effect on the entire pharmaceutical market and resulted in a major reorganization and integration of the sector.

This transaction has had a significant effect on the entire pharmaceutical market, and has resulted in a major reorganization and integration of the sector.

The Bernitsas Law team was led by Linda Vasaka. The Bernitsas Law team was led by Linda Vasaka. Lawyers from our Employment, Tax and Real Estate teams also advised on the transaction.